Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension

Inclusion Criteria: 1. Meet the condition of mean pulmonary arterial pressure (mPAP) ≥25 mmHg at seal level at rest and pulmonary capillary wedge pressure(PCWP)≤15mmHg; 2. Category 1 or 4 of PH in stable stage according to 2008 Dana Point Conference,including the idiopathic, hereditary, drugs and toxins induced, associated with connective tissue disease or congenital heart disease, and chronic thromboembolic pulmonary arterial hypertension(PAH) ; 3. Male or female between 15 to 70 years old; 4. WHO pulmonary hypertension functional class II or III; 5. The baseline 6-minute walk distance between 150-550 m; 6. Patients' condition should be stable for more than one month after basic treatment; For those patients with congenital heart disease, surgery should have been performed six months or more before they are enrolled in the study; 7. Patients receiving sildenafil treatment only previously, or those without target drugs treatment during the past 3 months; 8. Patients or their guardians should agree with this clinical trail and medical informed consent of the trial should be signed. Exclusion Criteria: 1. Unavailable or limited legal capacity; 2. Pregnant or lactational women; 3. Important organs with severe diseases; 4. Mental or physical disability; 5. With suspected or indeed alcohol, drug abuse history; 6. With allergic constitution, with two or more drugs or foods allergy history or those who are allergic to any components of the experimental drugs; 7. With both aspartate aminotransferase (AST) and glutamic-pyruvic transaminase (ALT) more than three times of the upper limit of normal in liver function test and Ccr≤50ml/min in kidney function test; 8. Those with systemic blood pressure\<90/50 mmHg, or those uncontrolled dangerous hypertension(BP\>170/110 mmHg); 9. Patients at active stages of infectious or other diseases such as hepatitis A, hepatitis B, AIDS, tuberculosis, and some connective tissue diseases; 10. Patients with severe infection, especially pulmonary infection; 11. Patients with shock or astable hemodynamics with other causes; 12. Patients with hepatic cirrhosis, and hepatic cirrhosis induced portal hypertension; 13. Patients with severe hemorrhage, and hemorrhagic tendency; 14. Patients who need to take or be taking drugs possible or indeed affecting this trial; 15. Patients cannot accomplish required items (especially 6MWD) because of acute/chronic organic disease (excluding dyspnea) or other illnesses such as lower extremity diseases; 16. Patients with any other conditions considered cannot be recruited.